The initiative will make use of DNA Script's enzymatic synthesis platform, which generates high-fidelity nucleic acids without the use of hazardous chemical solvents, the company said. Moderna will use these acids to produce messenger RNA therapeutics and vaccines. DNA Script will receive up to $5 million from DARPA.

Sanofi to provide fill/finish services for Moderna COVID-19 vaccine
Moderna has inked a new agreement with Sanofi in order to scale up U.S. manufacturing capacity for its COVID-19 vaccine.

Moderna provides updates on mRNA vaccine platform
Moderna gave updates on its messenger RNA (mRNA) vaccines during its second annual Vaccines Day event. The company plans to continue to invest resources...

Moderna highlights 6-month antibody persistence of its COVID-19 vaccine
Antibody persistence lasted through six months following the second dose of Moderna's COVID-19 vaccine, according to a study published April 6 in the...

Moderna announces administration of pediatric COVID-19 vaccine doses
Moderna announced that the first participants have been dosed in its phase II/III study of its pediatric messenger RNA (mRNA) COVID-19 vaccine candidate,...

DNA Script to contribute to DARPA's mobile vaccine manufacturing platform
DNA Script has been selected by GE Research to join a collaboration to develop a rapid response, mobile medical manufacturing platform to enable on-demand...